Oculus Innovative Sciences, Inc. (OCLS) Receives Regulatory Approvals for Three New Microcyn-Based Products in the Middle East
Global healthcare company Oculus Innovative Sciences has announced two new regulatory approvals in Kuwait, Iraq, and Dubai for three new Microcyn-based consumer products. The three products - all of which are targeted to be launched in fall 2013 - are Face Cool, which is a hydrogel for treating acne and various dermatoses; Baby Cool, which is a hydrogel for treating baby rash; and Lady Cool, which is a feminine hygiene wash.
Oculus is pleased to broaden its product portfolio to include consumer products in these key Middle East countries. The company's original Microcyn-based advanced wound management products have received acclaim from healthcare institutions throughout the region - many of which have reported a substantial decline in healthcare costs as a result of reduced infections, antibiotics, and hospitalization days. The data indicating these cost savings was used to support the regulatory filings for these latest consumer products.
"We are looking forward to the commercialization of these new and unique products this coming fall through our Dubai-based Microsafe Care Management subsidiary," said Dr. Walid Yousef, vice president of Joseph & Gionis, which is Oculus' master distributor in the Middle East.
Occulus, a worldwide healthcare company, is engaged in designing, manufacturing, and marketing prescription and nonprescription products in more than 20 countries. Oculus' products are used to treat patients in surgical/advanced wound management, dermatology, women's health, and animal health to address unmet medical needs in these markets - simultaneously raising the bar in patient care and lowering overall healthcare costs. Headquartered in Petaluma, Calif., Oculus has manufacturing operations in the U.S. and Latin America.
For more information, visit oculusis.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net